Yahoo Finance

Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or ...
Yahoo Finance

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value ...
Nasdaq

Fortress Biotech and Helocyte Launch Phase 2 Trial for CMV Vaccine Triplex in Stem Cell Transplant Recipients

Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
Business Wire

Triplex Meets Primary Endpoint in Phase 2 Clinical Trial, Reduces Rate of Cytomegalovirus (CMV) Complications in Transplant Recipients by 50 Percent

First prophylactic vaccine to demonstrate proof of concept for CMV control independent of human leukocyte antigen (HLA) status in stem cell transplant recipients DUARTE, Calif.--(BUSINESS WIRE)--City ...